Why Is Tyra Biosciences (TYRA) Stock Down -27.38% Today?
Key Takeaways
- Shares plunged roughly 27.38% to about $19.41 in early trading, down from a prior close of $26.73.
- Primary catalyst: Initial Phase 2 SURF302 efficacy data for lead candidate dabogratinib in intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC) came in below investor expectations.
- Secondary driver: Wall Street characterized the readout as "lukewarm," prompting a sharp repricing of the stock's risk-reward.
- Broader context: The move is company-specific rather than sector-wide, reflecting a binary clinical-data reaction typical of small- and mid-cap biotech names.
- What traders are watching next: Management's decision on advancing dabogratinib into a registrational study and upcoming safety-sentinel cohort data.
Opening Summary
TYRA, the Nasdaq-listed shares of Tyra Biosciences, Inc., a clinical-stage biotechnology company developing next-generation precision medicines targeting fibroblast growth factor receptor (FGFR) biology, tumbled sharply in Tuesday's session. The stock fell approximately 27.38% to trade near $19.41, down from a previous close of $26.73. The sell-off was driven by the company's release of initial Phase 2 SURF302 data for dabogratinib, its lead oral drug candidate, which markets judged to be weaker than hoped despite a relatively clean safety profile.
Catalyst Breakdown: Phase 2 SURF302 Data Disappoints
The dominant force behind the decline was the first clinical readout from the SURF302 study, which is evaluating dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle-invasive bladder cancer. While the data demonstrated a favorable safety profile — with no Grade 4 or 5 treatment-emergent adverse events — the efficacy results left investors wanting more. Grade 3 treatment-emergent adverse events were reported in 14% of patients at the 60 mg dose and 9% at the 50 mg dose.
Tyra Biosciences reported a 100% overall response rate and a 75% best overall response complete-response (CR) rate in single-marker lesion patients at the 60 mg dose, which management said supports selection of that dose for a registrational adjuvant strategy. However, the market's reaction suggests many investors had positioned for stronger efficacy or cleaner differentiation, and the initial readout failed to clear that bar.
Analyst Reaction: "Lukewarm, but Not Program Terminating"
Sell-side commentary amplified the negative price action. Analysts described the initial efficacy data as lower than expected, characterizing the readout as "lukewarm, but not program terminating." The view on the Street is that, while a lower efficacy outcome was within the range of possibilities, the company still has room to fine-tune its approach — and that the fundamental thesis of an oral drug providing meaningful patient convenience remains intact. Even so, the cautious tone weighed on sentiment and drove a swift repricing of the shares.
Market Context and Trading Activity
The move in TYRA was overwhelmingly company-specific. Trading volume was sharply elevated relative to the stock's recent daily averages, consistent with a news-driven, high-conviction reaction to a binary clinical catalyst. The decline diverged from the broader biotechnology complex, which did not experience a comparable drawdown, underscoring that the sell-off was tied to the SURF302 readout rather than to sector or macro pressure.
From a technical standpoint, the shares gapped down through multiple recent levels of support, erasing much of the gains accumulated in the prior weeks as investors positioned ahead of the data. The stock had climbed roughly 13% in the week leading into the announcement, making it especially vulnerable to a disappointment-driven reversal.
What Comes Next for TYRA
Looking ahead, the key near-term focus for TYRA is whether management proceeds to advance dabogratinib into a registrational trial in IR NMIBC, a decision that will shape the program's long-term value. Investors will also be watching for the initial safety-sentinel cohort results from the BEACH301 study, including six-month annualized growth velocity and safety data across multiple dose levels, which the company has guided toward the end of the first quarter of 2027.
Risks remain pronounced. As a clinical-stage company with no approved products, TYRA is dependent on future data readouts and regulatory outcomes, and additional volatility around binary catalysts is likely. Broader financing, execution, and competitive dynamics in the FGFR and bladder-cancer spaces will also remain important factors for investors to monitor.
Trending AI Robots
For traders seeking a more systematic approach to navigating volatile, catalyst-driven stocks, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a range of approaches to consider. Explore the Trending AI Robots page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TYRA's Indicator enters downward trend
The Aroon Indicator for TYRA entered a downward trend on September 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator formed such a pattern. In 175 of the 186 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TYRA as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for TYRA turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in 251 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. TYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.170) is normal, around the industry mean (26.780). P/E Ratio (21.787) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Interest Coverage Ratio?
What is Managerial Accounting and How Does Managerial Accounting Differ from Financial Accounting?
How Did Ticker Tape Evolve from Analog to Digital?
Week (June 2-6, 2025) in Review: Financial Leaders
Breakthrough in Swing Trading: Strategies, Backtesting, and AI-Powered Robots
General Information
Industry Biotechnology
Advertisement